This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Akili Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Akili has been growing earnings at an average annual rate of 7.6%, while the Healthcare Services industry saw earnings growing at 13.3% annually. Revenues have been growing at an average rate of 426.5% per year.

Belangrijke informatie

7.6%

Groei van de winst

48.1%

Groei van de winst per aandeel

Healthcare Services Groei van de industrie	12.9%
Inkomstengroei	426.5%
Rendement op eigen vermogen	-96.7%
Nettomarge	-2,492.0%
Laatste winstupdate	31 Mar 2024

Recente prestatie-updates uit het verleden

Recent updates

Opbrengsten en kosten

Hoe Akili geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

BMV:AKLI * Opbrengsten, kosten en inkomsten (USD Millions )
Datum	Inkomsten	Inkomsten	G+A Uitgaven	R&D-uitgaven
31 Mar 24	2	-49	39	18
31 Dec 23	2	-59	45	20
30 Sep 23	1	-65	52	23
30 Jun 23	0	2	55	26
31 Mar 23	0	-14	59	29
31 Dec 22	0	-19	62	29
30 Sep 22	0	-26	61	27
30 Jun 22	0	-99	58	24
31 Mar 22	0	-144	53	21
31 Dec 21	1	-127	43	18
30 Sep 21	0	-111	32	17
31 Dec 20	4	-26	14	15
31 Dec 19	20	-21	19	21

Kwaliteitswinsten: AKLI * is currently unprofitable.

Groeiende winstmarge: AKLI * is currently unprofitable.

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: AKLI * is unprofitable, but has reduced losses over the past 5 years at a rate of 7.6% per year.

Versnelling van de groei: Unable to compare AKLI *'s earnings growth over the past year to its 5-year average as it is currently unprofitable

Winst versus industrie: AKLI * is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (8%).

Rendement op eigen vermogen

Hoge ROE: AKLI * has a negative Return on Equity (-96.69%), as it is currently unprofitable.

This company listing is no longer active

Akili Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Belangrijke informatie

Recente prestatie-updates uit het verleden

Full year 2023 earnings released: US$0.76 loss per share (vs US$0.64 loss in FY 2022)

Akili, Inc. to Report Q4, 2023 Results on Feb 29, 2024

First quarter 2023 earnings released: US$0.27 loss per share (vs US$17.96 loss in 1Q 2022)

Recent updates

Akili, Inc.(NasdaqCM:AKLI) dropped from NASDAQ Composite Index

Akili to Delist from Nasdaq

Akili Announces FDA Authorization of EndeavorOTC, the First FDA Clearance of a Digital Treatment for Adults with AdHD Through a Video Game

Virtual Therapeutics Corp. entered into an agreement to acquire Akili, Inc. (NasdaqCM:AKLI) for $35 million.

Virtual Therapeutics Corp. entered into an agreement to acquire Akili, Inc. (NasdaqCM:AKLI) for $35 million.

Akili, Inc. to Reduce Workforce

Akili, Inc. Plans to Continue to Pursue Marketing Authorization from the U.S. Food and Drug Administration for Its EndeavorOTC Product

Akili, Inc. Receives A Letter from the Listing Qualifications Staff of the Nasdaq Stock Market LLC

Full year 2023 earnings released: US$0.76 loss per share (vs US$0.64 loss in FY 2022)

High number of new and inexperienced directors

Akili Announces Positive Results from Shionogi's Phase 3 Clinical Trial of Localized Version of Akili's Endeavorrx®? for Pediatric Adhd Patients in Japan

Akili, Inc. to Report Q4, 2023 Results on Feb 29, 2024

Akili, Inc. Announces Resignation of Santosh Shanbhag as Chief Financial Officer, Effective on January 12, 2024

Akili Receives Non-Compliance Notice from Nasdaq

Akili, Inc. Announces Kenneth Ehlert Resigns as A Member of the Board of Director, Member of the Audit Committee and Nominating and Corporate Governance Committee of the Board

Akili, Inc. Receives Authorization from the U.S. Food and Drug Administration

Akili Receives Non-Compliance Notice from Nasdaq

Akili, Inc. Releases Results from A New Study Examining the Way in Which Adhd Impacting the U.S. Workforce

Akili, Inc. Announces CEO Changes

Akili Releases EndeavorOTC on Android Devices, Expanding Treatment Access for Millions of Adults with Adhd

High number of new and inexperienced directors

Akili Releases EndeavorOTC Video Game Treatment to Improve Attention in Adults with Adad

Akili, Inc. to Present Clinical Data from Pivotal Trial of Video Game Treatment in Adolescents with Adolescents At 2023

First quarter 2023 earnings released: US$0.27 loss per share (vs US$17.96 loss in 1Q 2022)

High number of new and inexperienced directors

High number of new and inexperienced directors

Opbrengsten en kosten

Inkomsten en omzetgeschiedenis

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Rendement op eigen vermogen

Rendement op activa

Rendement op geïnvesteerd vermogen

Ontdek sterk presterende bedrijven uit het verleden